Is AMRI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

364 people get AMRI articles and Market Currents by email alert.

Get email alerts on AMRI »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Risk/Reward For Shares Of Albany Molecular Are Balanced After A 300% Run Up In Shares
Paul Nouri • Tue, Mar 19 • 4 Comments
AMRI Turnaround At Inflection Point
Len Zehr • Wed, Jun 6, 2012
Albany Molecular Turnaround Provides Investment Opportunity
Paul Nouri • Fri, Jun 1, 2012 • 5 Comments
The Recent Drop In Albany Molecular's Stock Price May Be Overdone
Paul Nouri • Thu, Nov 10, 2011 • 7 Comments

To learn more about Seeking Alpha Pro, click here.

Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • Sat, Apr 20 • 3 Comments
Q1 2013 Value Stock Screen Performance Summary
Jae Jun • Mon, Apr 8
5 Undervalued Healthcare Stocks That Analysts Love
ZetaKap • Wed, Aug 29, 2012 • 3 Comments
Consolidation Continues In Mid Cap DX Companies: Bull Market In Biotech Hits New Highs
Rod Raynovich • Wed, May 2, 2012 • 2 Comments
Biotech Bull Market Intact: Rayno Biopharmaceutical Portfolio Outperforms
Rod Raynovich • Mon, Apr 2, 2012
5 Biotech Stocks Undervalued By EPS Trends
Kapitall • Mon, Feb 13, 2012 • 2 Comments
10 Biotech Stocks Being Dumped By Big Money Managers
Kapitall • Tue, Aug 30, 2011 • 1 Comment
Future Biotech Superstars
ChartProphet • Wed, Mar 30, 2011 • 12 Comments
Our Investor Outlook: Cautious and Protected
ChartProphet • Tue, Mar 1, 2011 • 8 Comments
Sifting Through the Rubble of 2010: 9 Beaten Up, Deep-Value Small Caps
Alan Brochstein • Sun, Nov 28, 2010 • 4 Comments
Value Opportunities Created by Mutual Fund Selling
Alan Brochstein • Sun, Oct 31, 2010 • 8 Comments
Curis Tumbles on Failure of Cancer Drug Trial: Biotech's Latest Mishaps
The Burrill Report • Sun, Jun 20, 2010
19 'Bathwater Babies' and 20 'Dogs with Fleas' Stocks for the Week
J Clinton Hill • Sun, Mar 22, 2009 • 2 Comments
Jim Cramer's Mad Money Lightning Round, 1/24/08: Parexel-ance
SA Editor Miriam Metzinger • Fri, Jan 25, 2008

Albany Molecular Research's Management Presents at UBS Global Healthcare Conference (Transcript)
Wed, May 22
Albany Molecular Research's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 7
Albany Molecular Research's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Feb 12 • 1 Comment
Albany Molecular Research Q4 2008 Earnings Call Transcript
Mon, Feb 9, 2009
Albany Molecular Research, Inc. Q3 2008 Earnings Call Transcript
Tue, Nov 18, 2008
Albany Molecular Research, Inc. Q2 2008 Earnings Call Transcript
Sat, Aug 30, 2008
Albany Molecular Research Inc. Q1 2008 Earnings Call Transcript
Mon, May 5, 2008
Albany Molecular Research, Inc. Q4 2007 Earnings Call Transcript
Mon, Feb 11, 2008

Stocks to Watch: Stocks to watch Friday: Shutterfly, Rambus, CIT

at MarketWatch.com (Dec 23, 2011)
Biotech Stocks: Diet-drug makers move into spotlight

at MarketWatch.com (May 20, 2011)
Avoid the 'Too Big to Fail' Banks: Stock Picker

at CNBC.com (Nov 22, 2010)
Biotech Stocks: Biodel, stem-cell biotechs lead drug stock south

at MarketWatch.com (Aug 24, 2010)

AMRI vs. ETF Alternatives

Company Description

Currently, there's no company description for AMRI.

Sector: Services

Industry: Research Services

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 12, 2:44 PM The profitability of Albany Molecular's (AMRI +9.9%) "core business could reach historic levels," Sterne Agee says, citing the expected "resurgence in preclinical-PI activity over the next several years." Analyst Greg Bolan resumes coverage at Buy with a $15 price target. Comment! [Healthcare, On the Move]
Thursday, June 6, 11:03 AM Albany Molecular Research's (AMRI +0.5%) board unanimously votes to separate the role of chairman and CEO naming active board member, William S. Marth, as chairman, effective immediately. Comment! [Healthcare]
Tuesday, May 7, 12:52 PM Midday top 10 gainers: FSGI +28%. ARCI +27%. ININ +18%. MELI +18%. NLS +18%. PRTS +18%. REED +16%. PODD +14%. LAS +12%. MKTG +12%.
Midday top 10 losers: DCO -27%. RKUS -25%. GNK -24%. CUTR -23%. ARUN -22%. SNTA -15%. AMRI -12%. PIKE -12%. TA -12%. PTRY -11%. Comment! [On the Move]
Tuesday, May 7, 8:46 AM More on Albany Molecular Research's (AMRI) Q1: Contract revenue and margins rise 9% and 19% Y/Y respectively with the latter driven by improvements in the performance of the discovery and large scale manufacturing segments. The company reaffirms its FY13 revenue guidance (~12% growth) and ups its EPS outlook to $0.52-0.65 per share. (PR) Comment! [Healthcare, Earnings]
Tuesday, May 7, 8:09 AM Albany Molecular (AMRI): Q1 EPS of $0.23. Revenue of $59.4M (+11% Y/Y). Comment! [Earnings, Breaking News]
Sunday, April 14, 10:43 PM The rest of the top 25 June additions to the Russell 2000 expected by Credit Suisse: GNMK, AVIV, FBC, TTS, UNXL, GARS, REMY, BNCN, CBK, VRNG, LFVN, GTN, NLS, ENT, AMRI, POWR, DCO, INSM, CUTR, PPBI. "Very few of the bigger adds are owned by actively managed small cap funds," notes CS. Comment! [Quick Ideas]
Wednesday, February 13, 12:45 PM Midday top 10 gainers: RSOL +76%. RCON +27%. TRLA +25%. PRLB +24%. RPXC +22%. PRO +18%. ICAD +17%. PES +13%. AMRI +12%. VG +11%.
Midday top 10 losers: LTRE -21%. EZCH -21%. RATE -19%. RAX -18%. CLF -18%. MPG -17%. FBN -17%. NAII -16%. ATOS -14%. ZN -13%. Comment! [On the Move]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
Tuesday, February 12, 12:20 PM Albany Molecular Research (AMRI +18%) surges after its FQ3 easily blows out estimates this morning. Contract revenue was $59.1M, up 50% from the prior-year period with sequential revenue improvement in Discovery and Large Scale Manufacturing services. Contract margin jumped to 18% from 2% in the prior-year period. The company also forecast an upbeat Q4, now expecting an EPS of $0.08 - $0.12, better than the Street view of $0.06. Comment! [Earnings, On the Move]
Tuesday, February 12, 8:15 AM Albany Molecular (AMRI): Q4 EPS of $0.17 beats by $0.08. Revenue of $67.2M (+44% Y/Y) beats by $10.71M. (PR) Comment! [Earnings, Breaking News]
Tuesday, January 22, 12:45 PM Midday top 10 gainers: PBIB +32%. DQ +18%. TECUA +18%. ONP +17%. USEG +17%. RDCM +17%. CIMT +14%. BOX +14%. MTRX +12%. PRCP +12%.
Midday top 10 Losers: CALI -12%. OIBR -12%. BVX -10%. DOM -9%. ARNA -8%. IIVI -8%. AMRI -8%. UPI -8%. IPXL -8%. EXFO -7%. Comment! [On the Move]
Tuesday, November 20, 2012, 11:45 AM AngioDynamics (ANGO -0.5%) says its CFO, Joseph Gersuk, is stepping down in late January. Mr. Gersuk will be succeeded by Mark T. Frost, whose most recent position was as finance chief of Albany Molecular Research (AMRI +5.7%). Comment! [Healthcare]
Tuesday, November 6, 2012, 10:30 AM Albany Molecular Research (AMRI +11%) pops after beating on its Q3 bottom line this morning. Total sales were up 11.2% Y/Y on stronger royalty and contract revenues, particularly in its large-scale manufacturing segment. The company also boosts its outlook for FY12 as well as Q4. It now sees FY12 earnings coming in between $0.10 and $0.16 per share, towards the top-end of the Street's $0.12 consensus, and for Q4, its EPS is targeted to be $0.08 to $0.12, also better than the Street view of $0.06. Comment! [Healthcare, Earnings, On the Move]
Tuesday, November 6, 2012, 9:17 AM Albany Molecular Research (AMRI): Q3 EPS of $0.00 beats by $0.02. Revenue of $55.8M (+11.2% Y/Y). (PR) Comment! [Earnings, Healthcare]
Wednesday, August 1, 2012, 8:38 AM Albany Molecular Research (AMRI): Q2 EPS of $0.06 beats by $0.04. Revenue of $50M (-7.2% Y/Y) misses by $2M. (PR) Comment! [Earnings]
Wednesday, May 9, 2012, 8:22 AM Albany Molecular Research (AMRI): Q1 EPS of $0.02 misses by $0.03. Revenue of $53.7M (-5.6% Y/Y) beats by $1.5M. (PR) Comment! [Earnings, Healthcare]

smokeyRose
What Does Anyone think of$AMRI I'm thinking of Buying it.
May 14, 11:47 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

joeg1969
Adding $AMRI on the discount!
May 7, 12:41 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

joeg1969
$AMRI great buying opportunity on the discount!
Mar 15, 12:35 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Any one know anything about $AMRI? It's been on a tear & is under heavy accumulation after last earnings release. Stock +210% since Nov.
Mar 12, 2:14 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Closet Iguana
$AMRI -http://goo.gl/cMGe1
Feb 12, 10:41 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Undervalued Healthcare Stocks That Analysts Love http://bit.ly/Pt0E6e $ALR $AMRI $ATEC $CYH $WLP @ZetaKap
8/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chun Bong Lai
Sold YOKU (+6.29%, 29 days); currently holding NOK, FOSL, AMRI
2/16/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chun Bong Lai
After hour: F (up), AMRI (up), WYNN (down), MDLZ (down)
2/10/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dr. Kris
Short notice: Albany Molecular (AMRI) dropping over 40% in past several months is nearing the all-important $5 mark.
6/17/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

AMRI Albany Molecular Research, Inc.

AMRI

Albany Molecular Research, Inc.